SAVA Cassava Sciences

Cassava Sciences to Hold Corporate Update on November 25th

Cassava Sciences to Hold Corporate Update on November 25th

Webcast planned for Monday, November 25th at 8:00 AM ET

AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.

  
Event Details:
  
Date: Monday, November 25th
Time: 8:00 a.m. Eastern Time
Webcast:
  

A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences website for 90 days following the webcast.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam is a proprietary, investigational oral small molecule that targets the filamin A protein. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit:

For More Information Contact:

Investors

Sandya von der Weid

Media

Company

Eric Schoen, Chief Financial Officer

(512) 501-2450

 



EN
25/11/2024

Underlying

SAVACassava Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cassava Sciences

 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program...

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Borde...

May 1, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec,...

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announced the retirement of James W. Kupiec, MD, Chief Medical Officer, effective May 9, 2025. The Comp...

April 21, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to demonstrate an overall favorable safety profileCassava’s Alzheimer’s disease development program with simufilam will be completely discontinued by the end of Q2 2025 AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company f...

March 25, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Reports 2024 Financial Results and Provides Business ...

Cassava Sciences Reports 2024 Financial Results and Provides Business Update Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic application for simufilam for seizures related to tuberous sclerosis complex (TSC)$128.6 Million in Cash and Cash Equivalents at December 31, 2024 AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on dev...

March 3, 2025 1 EN
 PRESS RELEASE
Free
SAVA Cassava Science...

Cassava Sciences Licenses Simufilam Method of Treatment Patent

Cassava Sciences Licenses Simufilam Method of Treatment Patent Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of treatment patent for potential treatment with simufilam of seizures related to rare neurodevelopmental disordersThe licensed patent is based on research led by Yale University and published in Science Translational Medicine showing that treatment with simufilam appeared to meaningfully reduce seizure frequency in an animal modelCassava will prioritize initial development efforts on tubero...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch